{"id":8168,"date":"2023-08-05T06:30:10","date_gmt":"2023-08-05T06:30:10","guid":{"rendered":"https:\/\/mysourcefunding.com\/leadership\/how-hawthorne-effect-is-trying-to-effect-change-towards-more-accessible-clinical-trials-for-everyone\/"},"modified":"2023-08-05T06:30:11","modified_gmt":"2023-08-05T06:30:11","slug":"how-hawthorne-effect-is-trying-to-effect-change-towards-more-accessible-clinical-trials-for-everyone","status":"publish","type":"post","link":"https:\/\/mysourcefunding.com\/?p=8168","title":{"rendered":"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone"},"content":{"rendered":"
\n

According to Jodi Akin, clinical trials have what she calls \u201ca very large accessibility problem.\u201d<\/p>\n

Akin is founder and chief executive officer of Hawthorne Effect, a healthcare startup dedicated to reimagining clinical trials. On the company\u2019s website, the company states its mission is to \u201cdeliver innovative, accessible, inclusive clinical trials\u201d in an effort to \u201c[improve] the health and well-being of all humanity.\u201d<\/p>\n

Hawthorne Effect isn\u2019t alone in this endeavor\u2014or in this column. Last October, I interviewed Greenphire\u2019s Jaleeysa King about her company\u2019s own work in making clinical trials more diverse and accessible. King, a data analyst and co-chair of Greenphire\u2019s diversity committee, said in part trials \u201ccurrently do not adequately represent the full range of the population that is impacted by the disease being studied,\u201d adding that \u201chistorically lacked data for minority ethnic populations.\u201d<\/p>\n

In an interview via email earlier this week, Akin explained Hawthorne Effect\u2019s origin story traces back 8 years when, in 2015, she found herself faced with an opportunity to \u201ccorrect the accessibility and diversity shortcomings in clinical trials while making research part of real-world healthcare for both patients and clinicians.\u201d The industry\u2019s problems have had profound effects on her life, both personally and professionally. Those experiences spurred Akin on a journey towards what she described as \u201chealth equity and quality solutions that merge clinical research and innovative technology with compassion and accessibility within clinical trial participants\u2019 own communities.\u201d<\/p>\n

In a nutshell, Hawthorne Effect\u2019s raison d\u2019\u00eatre<\/em> is to fix the issues with clinical trials and accessibility and diversity. These shortcomings, Akin told me, have a tendency to result in less scientifically accurate trials that have immense reverberating costs. Not only do they cost billions of dollars in funding and function, the ultimate costs are \u201cearly deaths and poor health,\u201d Akin said.<\/p>\n

<\/fbs-ad><\/p>\n

\u201cAt Hawthorne Effect, we\u2019re doing both [solving accessibility and diversity] simultaneously,\u201d Amin said of her company\u2019s methodologies. \u201cOur unique approach incorporating technology and a distributed network of certified medical professionals enables us to bring trials directly to the patient, in their home, versus them having to travel hundreds of miles multiple times a year for follow-up appointments in a clinical setting. Our Hawthorne Heroes network also comes from the patients\u2019 trusted communities, making them feel more at ease and better represented.\u201d<\/p>\n

Akin cited a recent study whereby Hawthorne Effect \u201cdemonstrated our ability to reach diverse trial populations.\u201d Results revealed Akin and team were able to get 15% Black, 3% Asian, and 10% Hispanic people enrolled in trials. These numbers, she said, are markedly higher than typical industry averages.<\/p>\n

When asked who exactly is best served by more accessible trials, Akin was emphatic in responding that everyone is\u2014even those who generally are bountifully represented in research. And yet, problems persist. \u201cSadly, so many barriers\u2014 economic, demographic, sociographic and more\u2014remain in connecting patients with clinical trials. That\u2019s something Hawthorne Effect has intentionally set about correcting,\u201d she said.<\/p>\n

Like with countless other industries, technology has quite literally made Hawthorne Effect\u2019s work possible. Akin called the sheer existence of her company\u2019s platform \u201cunprecedented,\u201d saying it was \u201cbuilt from the ground up to enable scalable, compliant, and high-quality clinical trial visits to occur in the home.\u201d<\/p>\n

The platform matters because, Akin said, it enables Hawthorne Effect to meet people where they are in their lives. The reality is, it\u2019s difficult, if not impossible, for many people to miss work or get to a central location for trials. This is especially true for members of the disability community, whose logistical life in terms of managing transit and finances often must be dealt with with near surgical precision.<\/p>\n

Measure twice and cut once, indeed.<\/p>\n

\u201cBy meeting patients where they are most comfortable, in their homes, you are able to reach people who would have otherwise been unavailable,\u201d Akin said. \u201cJust a handful of years ago, it would not have been possible to do this in a way that was scalable from a logistics perspective or feasible from a quality and compliance perspective.\u201d<\/p>\n

Akin shared an anecdote about a 90-year-old woman named Opal. Opal, who started participating in trials at Stanford, was expected to travel thousand of miles for more than six months. Akin also pointed to staff workers juggling tight schedules, as well as parents of newborns being forced to consider dropping out of what she called \u201clife-saving trials\u201d due to travel concerns such as cost and distance.<\/p>\n

But it isn\u2019t only participants who can reap benefits from Hawthorne\u2019s model. Akin said trial sponsors and industry partners benefit largely because modern technology allows for better outcomes. \u201cBy providing them with cleaner, faster, comprehensive datasets, Hawthorne Effect accelerates regulatory approvals and time-to-market, she said. [This is true] for complex trials or during times when the industry is facing unprecedented barriers of its own, such as during the COVID pandemic.\u201d<\/p>\n

Akin continued: \u201cIf we step back for a moment, what appears is an opportunity to connect research generally with patient care, making it part of the individual healthcare experience. Because our technology enables community clinicians to serve in trials, that brings the doctor-patient relationship back home and promises truly personalized treatments.\u201d<\/p>\n

Feedback on Hawthorne Effect has been positive, Akin said. It\u2019s given the company opportunities to put their energy into trials that have \u201cfar-reaching impact.\u201d Moreover, Akin told me the company feels they\u2019ve reached an inflection point in the industry where a major paradigm shift is happening. \u201cChange doesn\u2019t tend to come quickly in our industry, or healthcare generally,\u201d she said. \u201cHowever, between the advancements in trial technology that Hawthorne Effect is using, the changes brought about by the pandemic and the willingness of regulatory groups like the FDA to engage and support new methodologies, we hear and see a great deal of enthusiasm in the industry around our approach.\u201d<\/p>\n

Going forward, Akin was forthright in saying her company has even bigger aspirations than making clinical trials more diverse and accessible. In the long-term, they wish to see trials become embedded within the overall continuum of care for every patient, such that research becomes part and parcel to how quality healthcare is delivered.<\/p>\n

\u201cIf we can make trials accessible to all patients and physicians, that truly brings the patient-doctor relationship back home,\u201d Akin said.<\/p>\n<\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

According to Jodi Akin, clinical trials have what she calls \u201ca very large accessibility problem.\u201d Akin is founder and chief executive officer of Hawthorne Effect, a healthcare startup dedicated to reimagining clinical trials. On the company\u2019s website, the company states its mission is to \u201cdeliver innovative, accessible, inclusive clinical trials\u201d in an effort to \u201c[improve] […]<\/p>\n","protected":false},"author":1,"featured_media":8169,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","footnotes":""},"categories":[76],"tags":[],"class_list":{"0":"post-8168","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-leadership"},"yoast_head":"\nHow Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone | Brandiary<\/title>\n<meta name=\"description\" content=\"According to Jodi Akin, clinical trials have what she calls \u201ca very large accessibility problem.\u201d Akin is founder and chief executive officer of Hawthorne\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mysourcefunding.com\/?p=8168\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone | Brandiary\" \/>\n<meta property=\"og:description\" content=\"According to Jodi Akin, clinical trials have what she calls \u201ca very large accessibility problem.\u201d Akin is founder and chief executive officer of Hawthorne\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mysourcefunding.com\/?p=8168\" \/>\n<meta property=\"og:site_name\" content=\"Brandiary\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-05T06:30:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-05T06:30:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/08\/1691217010_0x0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1248\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/mysourcefunding.com\/?p=8168#article\",\"isPartOf\":{\"@id\":\"https:\/\/mysourcefunding.com\/?p=8168\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/mysourcefunding.com\/#\/schema\/person\/5062dafb0f932b59aa228f1a047332f4\"},\"headline\":\"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone\",\"datePublished\":\"2023-08-05T06:30:10+00:00\",\"dateModified\":\"2023-08-05T06:30:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/mysourcefunding.com\/?p=8168\"},\"wordCount\":1067,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/mysourcefunding.com\/#organization\"},\"articleSection\":[\"Leadership\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/mysourcefunding.com\/?p=8168#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/mysourcefunding.com\/?p=8168\",\"url\":\"https:\/\/mysourcefunding.com\/?p=8168\",\"name\":\"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone | Brandiary\",\"isPartOf\":{\"@id\":\"https:\/\/mysourcefunding.com\/#website\"},\"datePublished\":\"2023-08-05T06:30:10+00:00\",\"dateModified\":\"2023-08-05T06:30:11+00:00\",\"description\":\"According to Jodi Akin, clinical trials have what she calls \u201ca very large accessibility problem.\u201d Akin is founder and chief executive officer of Hawthorne\",\"breadcrumb\":{\"@id\":\"https:\/\/mysourcefunding.com\/?p=8168#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/mysourcefunding.com\/?p=8168\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/mysourcefunding.com\/?p=8168#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/mysourcefunding.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/mysourcefunding.com\/#website\",\"url\":\"https:\/\/mysourcefunding.com\/\",\"name\":\"Brandiary\",\"description\":\"Latest Business and Startup News and Updates\",\"publisher\":{\"@id\":\"https:\/\/mysourcefunding.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/mysourcefunding.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/mysourcefunding.com\/#organization\",\"name\":\"Brandiary\",\"url\":\"https:\/\/mysourcefunding.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mysourcefunding.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/06\/b-logo-1.png\",\"contentUrl\":\"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/06\/b-logo-1.png\",\"width\":381,\"height\":100,\"caption\":\"Brandiary\"},\"image\":{\"@id\":\"https:\/\/mysourcefunding.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/mysourcefunding.com\/#\/schema\/person\/5062dafb0f932b59aa228f1a047332f4\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/mysourcefunding.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/06\/avatar_user_1_1688031660-96x96.png\",\"contentUrl\":\"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/06\/avatar_user_1_1688031660-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/mysourcefunding.com\"],\"url\":\"https:\/\/mysourcefunding.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone | Brandiary","description":"According to Jodi Akin, clinical trials have what she calls \u201ca very large accessibility problem.\u201d Akin is founder and chief executive officer of Hawthorne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mysourcefunding.com\/?p=8168","og_locale":"en_US","og_type":"article","og_title":"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone | Brandiary","og_description":"According to Jodi Akin, clinical trials have what she calls \u201ca very large accessibility problem.\u201d Akin is founder and chief executive officer of Hawthorne","og_url":"https:\/\/mysourcefunding.com\/?p=8168","og_site_name":"Brandiary","article_published_time":"2023-08-05T06:30:10+00:00","article_modified_time":"2023-08-05T06:30:11+00:00","og_image":[{"width":1200,"height":1248,"url":"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/08\/1691217010_0x0.jpg","type":"image\/jpeg"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mysourcefunding.com\/?p=8168#article","isPartOf":{"@id":"https:\/\/mysourcefunding.com\/?p=8168"},"author":{"name":"News Room","@id":"https:\/\/mysourcefunding.com\/#\/schema\/person\/5062dafb0f932b59aa228f1a047332f4"},"headline":"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone","datePublished":"2023-08-05T06:30:10+00:00","dateModified":"2023-08-05T06:30:11+00:00","mainEntityOfPage":{"@id":"https:\/\/mysourcefunding.com\/?p=8168"},"wordCount":1067,"commentCount":0,"publisher":{"@id":"https:\/\/mysourcefunding.com\/#organization"},"articleSection":["Leadership"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/mysourcefunding.com\/?p=8168#respond"]}]},{"@type":"WebPage","@id":"https:\/\/mysourcefunding.com\/?p=8168","url":"https:\/\/mysourcefunding.com\/?p=8168","name":"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone | Brandiary","isPartOf":{"@id":"https:\/\/mysourcefunding.com\/#website"},"datePublished":"2023-08-05T06:30:10+00:00","dateModified":"2023-08-05T06:30:11+00:00","description":"According to Jodi Akin, clinical trials have what she calls \u201ca very large accessibility problem.\u201d Akin is founder and chief executive officer of Hawthorne","breadcrumb":{"@id":"https:\/\/mysourcefunding.com\/?p=8168#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mysourcefunding.com\/?p=8168"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/mysourcefunding.com\/?p=8168#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mysourcefunding.com\/"},{"@type":"ListItem","position":2,"name":"How Hawthorne Effect Is Trying To Effect Change Towards More Accessible Clinical Trials For Everyone"}]},{"@type":"WebSite","@id":"https:\/\/mysourcefunding.com\/#website","url":"https:\/\/mysourcefunding.com\/","name":"Brandiary","description":"Latest Business and Startup News and Updates","publisher":{"@id":"https:\/\/mysourcefunding.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mysourcefunding.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mysourcefunding.com\/#organization","name":"Brandiary","url":"https:\/\/mysourcefunding.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mysourcefunding.com\/#\/schema\/logo\/image\/","url":"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/06\/b-logo-1.png","contentUrl":"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/06\/b-logo-1.png","width":381,"height":100,"caption":"Brandiary"},"image":{"@id":"https:\/\/mysourcefunding.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/mysourcefunding.com\/#\/schema\/person\/5062dafb0f932b59aa228f1a047332f4","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mysourcefunding.com\/#\/schema\/person\/image\/","url":"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/06\/avatar_user_1_1688031660-96x96.png","contentUrl":"https:\/\/mysourcefunding.com\/wp-content\/uploads\/2023\/06\/avatar_user_1_1688031660-96x96.png","caption":"News Room"},"sameAs":["https:\/\/mysourcefunding.com"],"url":"https:\/\/mysourcefunding.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=\/wp\/v2\/posts\/8168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8168"}],"version-history":[{"count":1,"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=\/wp\/v2\/posts\/8168\/revisions"}],"predecessor-version":[{"id":8170,"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=\/wp\/v2\/posts\/8168\/revisions\/8170"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=\/wp\/v2\/media\/8169"}],"wp:attachment":[{"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mysourcefunding.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}